2 days ago
Cipla’s InvaGen Plant Gets USFDA VAI Classification for Inspection
Cipla owns a US company called InvaGen Pharmaceuticals.
InvaGen makes generic medicines at a plant in New York.
The USFDA recently inspected that plant.
The regulator labeled the inspection result VAI.
This means inspectors noticed some problems or practices that need attention.
However, the USFDA did not say the issues required formal enforcement action.
Cipla did not explain what the inspectors found or what fixes it may make.
The company reported the result to stock exchanges.
The USFDA classified a recent inspection at Cipla subsidiary InvaGen’s Unit 3 facility as Voluntary Action Indicated.
The plant is located in Central Islip, Long Island, New York, and manufactures generic drug formulations for the US market.
A VAI classification means inspectors found objectionable conditions or practices but did not recommend formal regulatory action.
Cipla’s filing did not disclose the inspection observations, the number of cited items, or planned corrective measures.
Cipla’s share price was down 0.53% intraday on August 31, and had declined 4.28% over one month and 10.89% over one year.
- Who
- Cipla, its wholly owned subsidiary InvaGen Pharmaceuticals, and the US Food and Drug Administration.
- What
- The USFDA classified a recent inspection of InvaGen’s Unit 3 manufacturing facility as Voluntary Action Indicated.
- Where
- InvaGen’s Unit 3 facility in Central Islip on Long Island, New York.
- When
- The inspection was described as recent; Cipla’s disclosure updated an earlier July 18 filing, and the share-price data was reported as of August 31.
- Why
- The facility is subject to USFDA surveillance as part of its role in supplying generic medicines to the US market, and Cipla was required to disclose the material inspection update.
Key facts
- Inspection outcome
- Voluntary Action Indicated (VAI)
- Inspected facility
- Unit 3, InvaGen Pharmaceuticals Inc.
- Location
- Central Islip, Long Island, New York
- Regulatory meaning
- Objectionable conditions or practices were noted, but formal regulatory action was not warranted.
- Disclosure venues
- BSE, National Stock Exchange and Luxembourg Stock Exchange
- Cipla share price
- Down 0.53% intraday on August 31
- Longer-term performance
- Down 4.28% over one month and 10.89% over one year
Sources
Related news
US FDA Inspection Finds Three Observations at Apitoria Plant
Dr Reddy's receives four USFDA observations for Hyderabad plant
Aurobindo's Eugia Pharma Telangana Unit Gets USFDA Warning Letter
USFDA Warns Reliance Life Sciences Over Navi Mumbai Drug Lapses
USFDA Warns Dabur India Over Manufacturing Lapses at Silvassa Plant
